Tenax Therapeutics (TENX) Retained Earnings (2011 - 2026)
Tenax Therapeutics (TENX) posted quarterly Retained Earnings of $514.6 million for Q2 2026, up 17.09% year-over-year from $439.4 million in Q2 2025, and up 3.35% on a QoQ basis from $497.9 million in Q1 2026.
Tenax Therapeutics (TENX) Retained Earnings (2011 - 2026) Analysis & Trends
Tenax Therapeutics has reported Retained Earnings for 15 years, with the latest figure at $514.6 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at $514.6 million, up 17.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $514.6 million (up 17.09% YoY), and the FY2025 annual result was $464.5 million, up 14.18% from the prior year.
- Retained Earnings climbed to $514.6 million in Q2 2026, from $497.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $514.6 million in Q2 2026 and troughed at $282.8 million in Q1 2022.
- A 5-year average of $367.5 million and a median of $313.5 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings jumped 207.14%; it then advanced 2.7% in 2024.
- A 5-year view of Retained Earnings shows it stood at $291.0 million in 2022, then grew by 4.92% to $305.4 million in 2023, then jumped by 33.24% to $406.8 million in 2024, then advanced by 14.18% to $464.5 million in 2025, then climbed by 10.77% to $514.6 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $514.6 million in Q2 2026, $497.9 million in Q1 2026, and $464.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | 514.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 514.56 Mn |
| Mar 31, 2026 | 497.86 Mn |
| Dec 31, 2025 | 464.52 Mn |
| Sep 30, 2025 | 448.12 Mn |
| Jun 30, 2025 | 439.44 Mn |
| Mar 31, 2025 | 434.55 Mn |
| Dec 31, 2024 | -314.86 Mn |
| Sep 30, 2024 | 405.81 Mn |
| Jun 30, 2024 | 313.50 Mn |
| Mar 31, 2024 | -301.05 Mn |
| Dec 31, 2023 | -297.25 Mn |
| Sep 30, 2023 | -294.03 Mn |
| Jun 30, 2023 | -292.06 Mn |
| Mar 31, 2023 | -290.95 Mn |
| Dec 31, 2022 | -289.54 Mn |
| Sep 30, 2022 | 290.94 Mn |
| Jun 30, 2022 | -284.08 Mn |
| Mar 31, 2022 | 282.82 Mn |
| Dec 31, 2021 | -278.49 Mn |
| Sep 30, 2021 | 282.52 Mn |